|1.||Maurois, Pierre: 1 article (04/2008)|
|2.||Pages, Nicole: 1 article (04/2008)|
|3.||Vamecq, Joseph: 1 article (04/2008)|
|4.||Gressens, Pierre: 1 article (04/2008)|
|5.||Bac, Pierre: 1 article (04/2008)|
|6.||Stables, James P: 1 article (04/2008)|
|7.||Rocchi, Stéphane: 1 article (04/2008)|
04/01/2008 - "FMOC-L-leucine (up to 100 mg/kg) was inactive in the 6 Hz seizure test, an adult animal model largely responsive to anti-seizure drugs. "
04/01/2008 - "The PPARgamma agonist FMOC-L-leucine is likely to be devoid of these classic protective mechanisms because of its inactivity in the 6 Hz seizure test, its activity in the audiogenic test being explained by neuroprotective rather than intrinsic anti-seizure mechanisms. "
04/01/2008 - "In adult magnesium-deficient mice, a model responsive to both neuroprotective and anti-seizure compounds, FMOC-L-leucine, but not rosiglitazone, protected against audiogenic seizures. "
04/01/2008 - "The protection afforded by FMOC-L-leucine was alleviated by the PPARgamma antagonist GW9662 (1-2 mg/kg) and was induced in 50% animals by 4.8+/-1.2 mg/kg. At this dose, FMOC-L-leucine modified audiogenic seizure phase durations in convulsing mice differently than prototype antiepileptic drugs did. "
|2.||Brain Injuries (Brain Injury)
04/01/2008 - "In a model of neonatal brain injury, FMOC-L-leucine (4 microg/kg) was neuroprotective against cerebral ibotenate toxicity. "
04/01/2008 - "(N-[9-fluorenylmethoxycarbonyl]-)-L-leucine (FMOC-L-leucine) and rosiglitazone, two ligands of peroxisome proliferator-activated receptor gamma (PPARgamma), were evaluated in mature (adult mice) and immature (pups) brain injury models. "
|5.||Anticonvulsants (Antiepileptic Drugs)